Pfizer ends development of potential pill obesity treatment [CNN]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: CNN
The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment. The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said. The company intended to move the drug into late-stage testing, which is generally the last phase of development before a company submits the potential treatment to government regulators for approval. Ad Feedback A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing. Obesity treatments have become one of the more promising and lucrative sectors of drug development for pharmaceutical companies. Eli Lilly and Co.'s Zepbound, for instance, brought in nearly $5 billion in sales in 2024, its first full year on the market. Ad Feedback But l
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings [Yahoo! Finance]Yahoo! Finance
- Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance [Yahoo! Finance]Yahoo! Finance
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 GuidanceBusiness Wire
PFE
Earnings
- 11/4/25 - Beat
PFE
Sec Filings
- 12/16/25 - Form 8-K
- 12/2/25 - Form 4
- 11/21/25 - Form 8-K
- PFE's page on the SEC website